此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 Infection

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV Infection in Subjects Who Are Positive for HPV16/18

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All participants must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. Subjects who meet all inclusion criteria will report to the study site on Day 0 and be assigned to a specific dosage group. Following the completion of eligibility assessments and baseline safety evaluations, subjects will receive an injection of the HPV-targeting nucleic acid therapeutic on Day 0, Day 21 (±3 days), and Day 42 (±3 days).

研究概览

地位

招聘中

干预/治疗

详细说明

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All subjects must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. The study is divided into two phases:

Phase 1: This phase includes two dosage groups-0.05 mg and 0.5 mg. Subjects will be assigned to one of these dosage groups according to pre-established allocation rules and will receive a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

Phase 2: This phase consists of a 0.5 mg dosage group, with subjects receiving a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

研究类型

介入性

注册 (估计的)

300

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Hebei
      • Qinhuangdao、Hebei、中国
        • 招聘中
        • Beidaihe Hospital of Qinhuangdao City
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 64年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Participants must be aged 18-64 years (inclusive); only female participants will be enrolled.
  2. Subjects will voluntarily join the study and sign an informed consent form.
  3. During the screening period, there shall be no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, or clinical laboratory test results; the investigator will determine that the subject is suitable for enrollment.
  4. During the screening period, the HPV16/18 genotyping nucleic acid test result must be positive, and the subject must meet one of the following criteria: (1) a positive HPV16/18 test record during the screening period, with no current evidence of intraepithelial lesions; (2) a diagnosis of high-grade intraepithelial lesions of the cervix, vagina, or vulva confirmed by histopathological examination, with the subject meeting the enrollment criteria and treatment plan after specialist assessment; (3) the subject has previously undergone surgery or other local treatment for a related intraepithelial lesion, and the HPV16/18 test remains positive during the screening period, with no residual lesions currently present, or histopathological examination confirms the presence of residual or recurrent low-grade or high-grade intraepithelial lesions. (HPV subtype test results obtained within 30 days prior to administration, as well as TCT results and pathological biopsy results obtained within 90 days prior to administration, are acceptable).
  5. Fertile subjects (defined as females who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, and whose menopause has occurred for ≥12 months) must agree to use highly effective contraceptive measures with their partner during the study treatment period and for at least 12 months after the final dose, including oral contraceptives, intrauterine devices, barrier contraception combined with spermicidal agents, or partner sterilization.
  6. Female subjects during the screening period must have negative serum or urine pregnancy tests and must not be in the lactation period. Be willing to undergo pregnancy testing during the screening period, before each dose administration, and at the end of the study.
  7. Be willing and able to comply with and complete all study procedures.

Exclusion Criteria:

  1. Presence of any skin condition on the upper arm that may interfere with the assessment of the injection-site reaction (ISR), including but not limited to extensive tattoos, scars, rashes, infections, or wounds.
  2. Presence of severe poor venous condition that precludes blood sample collection as required by the protocol.
  3. Presence, during screening, of an acute infection of the genital or anal region requiring systemic anti-infective therapy (excluding HPV infection).
  4. Pregnancy or lactation; or a history of miscarriage within the 3 months preceding screening.
  5. Any medical condition judged by the investigator to increase the risk of biopsy-related bleeding.
  6. In addition to the study indication, any clinically significant acute or chronic disease that, as judged by the investigator, may increase the risk of trial drug exposure or interfere with study evaluation.
  7. Inadequacy for adequate colposcopic evaluation.
  8. Presence of any of the following conditions: 1) Pathological confirmation of adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma in the target lesion during the screening period; 2) A history of malignant tumors of the cervix, vagina, vulva, or anal region; 3) Colposcopic findings during the screening period suggesting a suspicious malignant tumor; 4) Having undergone total hysterectomy, thereby precluding assessment of cervical lesions (however, if the uterus was resected solely for benign lesions while the patient still has vulvar/vaginal/anal lesions, this does not automatically disqualify the subject); 5) Presence of any other uncurated malignant tumor in a site other than those described above within 5 years prior to enrollment (excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc.).
  9. Screening: Use of immunosuppressants continuously (for more than 7 days) within the 30 days prior to screening, including but not limited to: glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
  10. Screening: Receipt of any medication known to have anti-HPV activity (including injectable HPV prophylactic vaccines) within the 30 days prior to screening.
  11. History of severe allergic reactions (requiring hospitalization), severe reactions to any medication or vaccine injection, or any known or suspected allergy to any component of the study drug or formulation.
  12. Presence of uncontrolled systemic chronic diseases.
  13. Laboratory tests during the screening period meeting any of the following criteria: 1) Hemoglobin <90 g/L; 2) Neutrophil count <1.0 × 10⁹/L; 3) Platelet count <80 × 10⁹/L; 4) AST or ALT> 1.5 × ULN; 5) Creatinine clearance <60 mL/min (using the Cockcroft-Gault formula); 6) International Normalized Ratio (INR)> 1.5 × ULN; 7) HIV antibody positive; 8) HCV antibody positive (and HCV RNA positive); 9) HBsAg positive (and HBV DNA positive); 10) Active syphilis (RPR/TPPA positive and requiring treatment).
  14. Any history of alcohol or drug abuse that the Investigator deems likely to affect subject safety or study adherence.
  15. Subjects that the Investigator deems unwilling or unable to adhere to the requirements of the study protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:AVL-1100

Dosage and administration for the nucleic acid-based therapeutic injection for HPV infection: A total of 3 injections are to be administered, with an interval of three weeks between each dose. The product is to be administered via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the subject must remain under observation for 60 minutes, during which time a safety assessment will be conducted. Provided no serious adverse events occur, the subject may proceed with the scheduled follow-up visits.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and tolerability
大体时间:Up to Day 300

Dose-limiting toxicities (DLTs), as well as the incidence and severity of adverse events, etc.

Up to Day 300

次要结果测量

结果测量
措施说明
大体时间
Effectiveness
大体时间:Up to Day 300

The rate of HPV16/18 viral reversion to negativity at the final visit.

Up to Day 300
Effectiveness
大体时间:Up to Day 300

The degree of lesion regression assessed by histopathological evaluation at the final visit.

Up to Day 300
Immunogenic
大体时间:Up to Day 300

Cell-mediated antigen-specific immune response against HPV16/18.

Up to Day 300

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月21日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年10月28日

首先提交符合 QC 标准的

2026年11月14日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月14日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • AVL-1100-01

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅